JP2005505579A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505579A5
JP2005505579A5 JP2003530818A JP2003530818A JP2005505579A5 JP 2005505579 A5 JP2005505579 A5 JP 2005505579A5 JP 2003530818 A JP2003530818 A JP 2003530818A JP 2003530818 A JP2003530818 A JP 2003530818A JP 2005505579 A5 JP2005505579 A5 JP 2005505579A5
Authority
JP
Japan
Prior art keywords
xaa
formula
igf receptor
receptor antagonist
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003530818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505579A (ja
Filing date
Publication date
Priority claimed from US09/962,756 external-priority patent/US6875741B2/en
Application filed filed Critical
Publication of JP2005505579A publication Critical patent/JP2005505579A/ja
Publication of JP2005505579A5 publication Critical patent/JP2005505579A5/ja
Pending legal-status Critical Current

Links

JP2003530818A 2001-09-24 2002-09-24 アンタゴニスト Pending JP2005505579A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/962,756 US6875741B2 (en) 1998-09-02 2001-09-24 Insulin and IGF-1 receptor agonists and antagonists
PCT/US2002/030412 WO2003027246A2 (en) 2001-09-24 2002-09-24 Antagonists

Publications (2)

Publication Number Publication Date
JP2005505579A JP2005505579A (ja) 2005-02-24
JP2005505579A5 true JP2005505579A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=25506313

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003569654A Pending JP2005517741A (ja) 2001-09-24 2002-09-24 インシュリン及びigf−1レセプターのアゴニスト及びアンタゴニスト
JP2003530818A Pending JP2005505579A (ja) 2001-09-24 2002-09-24 アンタゴニスト

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003569654A Pending JP2005517741A (ja) 2001-09-24 2002-09-24 インシュリン及びigf−1レセプターのアゴニスト及びアンタゴニスト

Country Status (6)

Country Link
US (1) US6875741B2 (cg-RX-API-DMAC7.html)
EP (2) EP1432433A4 (cg-RX-API-DMAC7.html)
JP (2) JP2005517741A (cg-RX-API-DMAC7.html)
AU (2) AU2002366384A1 (cg-RX-API-DMAC7.html)
CA (2) CA2459999A1 (cg-RX-API-DMAC7.html)
WO (2) WO2003027246A2 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US6521738B2 (en) * 1999-12-29 2003-02-18 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogs
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
AU2003205830A1 (en) 2002-01-23 2003-09-02 Mohamed Raafat El-Gewely Molecular libraries
US7261876B2 (en) * 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP2385132B1 (en) * 2002-04-22 2014-03-05 Oncolix, Inc. Multimeric ligands with enhanced stability
NZ571508A (en) * 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CA2493532C (fr) * 2002-07-31 2014-05-27 Yves Saint-Laurent Parfums Cellules souches issues de tissu adipeux et cellules differenciees issues de ces cellules
US20040176291A1 (en) * 2002-09-24 2004-09-09 Elly Nedivi Methods and compositions for soluble CPG15
US7638605B2 (en) * 2003-05-01 2009-12-29 ImClone, LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US20050187175A1 (en) * 2003-09-30 2005-08-25 Elly Nedivi Methods and compositions for CPG15-2
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
WO2005082415A2 (en) * 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
EP1755660B1 (en) * 2004-05-07 2010-03-24 The University of North Carolina at Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-i
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
JP2008510692A (ja) * 2004-08-20 2008-04-10 ノボ ノルディスク アクティーゼルスカブ 薬学的に活性なインスリン受容体調節分子
US20090197800A1 (en) * 2004-10-27 2009-08-06 Novo Nordisk A/S Insulin Receptor Binding Peptides with Non-Insulin Gene Activation Profiles and Uses Thereof
AU2005305157B2 (en) * 2004-10-27 2011-09-01 Oklahoma Medical Research Foundation Adrenocorticotropic hormone analogs and related methods
EP2281841A3 (en) * 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarkers for pre-selection of patients for anti-IGF1R therapy
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
NZ586780A (en) 2005-03-23 2012-02-24 Genmab As Antibodies against CD38 for treatment of multiple myeloma
US20060233810A1 (en) * 2005-04-15 2006-10-19 Yaolin Wang Methods and compositions for treating or preventing cancer
NZ564098A (en) 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
RU2502523C2 (ru) 2005-06-17 2013-12-27 Имклоун Элэлси АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ
WO2007011610A2 (en) * 2005-07-18 2007-01-25 Acologix, Inc. Protein formulation for promoting hard tissue formation
CN101321780A (zh) * 2005-10-05 2008-12-10 诺沃-诺迪斯克有限公司 胰岛素受体拮抗剂及相关组合物、用途和方法
EA017265B1 (ru) * 2006-02-03 2012-11-30 Имклоун Элэлси Применение антитела imc-a12, которое является ингибитором igf-ir, для лечения рака предстательной железы
WO2007095113A2 (en) * 2006-02-10 2007-08-23 Massachusetts Institute Of Technology Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
EP2468767B1 (en) 2006-06-22 2015-10-28 Walter and Eliza Hall Institute of Medical Research Structure of the insulin receptor ectodomain
US20080064039A1 (en) * 2006-07-06 2008-03-13 Pienkos Philip T Dominant negative ligand drug discovery system
CN101802001A (zh) 2007-04-24 2010-08-11 安提拉公司 Igf-1r结合性蛋白和拮抗剂
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US20110189206A1 (en) 2008-01-03 2011-08-04 Barbas Iii Carlos F Antibody Targeting Through a Modular Recognition Domain
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
CA2713348C (en) 2008-01-30 2018-10-09 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2376099A4 (en) * 2008-12-19 2012-04-25 Univ Indiana Res & Tech Corp INSULIN AGAIN YL-BASED GROWTH FACTORS WITH HIGH ACTIVITY AT THE INSULIN RECEPTOR
CA2747490C (en) 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Insulin analogs
US9155801B2 (en) 2009-05-28 2015-10-13 The United States Government As Represented By The Department Of Veterans Affairs Amino acid sequences which enhance peptide conjugate solubility
EP2470201A4 (en) * 2009-08-28 2013-01-30 Bayer Healthcare Llc COFACTORS ENABLING THE THROMBINIC ACTIVATION OF FACTOR VII AND THEIR USES
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
CA2803164C (en) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
CA2825894C (en) 2011-02-02 2021-11-30 Amgen Inc. Prognosis of cancer using a circulating biomarker
EP2712423A4 (en) * 2011-02-25 2015-06-10 Wellstat Diagnostics Llc Assays for detecting enzymatic activity
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
AU2012267492A1 (en) * 2011-06-10 2014-01-09 President And Fellows Of Harvard College Modulation of pancreatic beta cell proliferation
EP2776042B1 (en) 2011-11-11 2019-03-20 Duke University Combination drug therapy for the treatment of solid tumors
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
US9073996B2 (en) 2012-08-31 2015-07-07 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (IGF-1)
CA2886228A1 (en) 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EA201890895A1 (ru) 2013-03-15 2019-02-28 Зинджения, Инк. Мультивалентные и моновалентные мультиспецифические комплексы и их применение
MX388301B (es) 2014-09-03 2025-03-19 Boehringer Ingelheim Int Il-23a y tnf-alfa orientados y compuesto y sus usos.
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
EP3206710B1 (en) 2014-09-24 2020-05-06 Indiana University Research & Technology Corporation Incretin-insulin conjugates
US11634470B2 (en) * 2015-10-23 2023-04-25 Jai Prakash Integrin binding peptides and uses thereof
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
WO2021146657A1 (en) * 2020-01-16 2021-07-22 The Translational Genomics Research Institute Methods of identifying synthetic molecular binding agents
WO2022020246A1 (en) * 2020-07-23 2022-01-27 The Scripps Research Institute Insulin receptor-mediated enhancement of gene transfer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
EP0378671B1 (en) * 1988-06-30 1997-03-12 City Of Hope Insulinomimetic and insulin receptor binding site peptides
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
JPH07508025A (ja) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子(igf−1)類似体
DE4432943A1 (de) 1994-09-15 1996-03-21 Radulescu Razvan T Dr Med M D Numerical Mirror Image Strategy (NUMIS)
RU2078769C1 (ru) 1995-08-18 1997-05-10 Научно-исследовательский институт биомедицинской химии РАМН Пептидный фрагмент, обладающий биологической активностью инсулина
US5912160A (en) 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
US6028053A (en) * 1995-10-27 2000-02-22 Mount Sinai Hospital Corporation Peptide inhibitors of a phosphotyrosine-binding domain containing protein
JP2000515726A (ja) 1996-06-07 2000-11-28 ジェネティックス・インスチチュート・インコーポレーテッド 分泌蛋白をコードする成人pbmc由来のポリヌクレオチド
ATE296446T1 (de) * 1997-01-15 2005-06-15 Telik Inc Modulatoren von insulinrezeptor-aktivität
EP1034188B1 (en) 1997-11-27 2006-06-07 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to igf receptor (1-462)
WO2000040613A1 (en) * 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
EP2368902A3 (en) * 2000-03-29 2011-12-21 DGI Bio Technologies LLC Insulin and IGF-1 receptor agonists and antagonists

Similar Documents

Publication Publication Date Title
JP2005505579A5 (cg-RX-API-DMAC7.html)
CN1038841C (zh) 新型多肽以及由其制备的抗人类免疫缺陷病毒制剂
JP2006149395A5 (cg-RX-API-DMAC7.html)
JP2005516072A5 (cg-RX-API-DMAC7.html)
JP2010510315A5 (cg-RX-API-DMAC7.html)
IN2014CN02050A (cg-RX-API-DMAC7.html)
AU2003264514A1 (en) Wt1 substitution peptides
JP2005519059A5 (cg-RX-API-DMAC7.html)
JP2004267216A5 (cg-RX-API-DMAC7.html)
WO2006029411A3 (en) Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
CA2411786A1 (en) A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
JP2005516996A5 (cg-RX-API-DMAC7.html)
JP2011072294A (ja) 新規抗菌ペプチド
CN110563802B (zh) 一组含n-甲基化氨基酸及n端脂肪酸修饰的抗菌肽类似物及其合成方法和应用
WO2009120831A8 (en) Novel n-and c-terminal substituted -antagonistic analogs of human gh-rh
OA10030A (en) Novel polypeptide and anti-hiv drug prepared therefrom
WO2008113536A8 (en) Neurotrophic peptides
Moss et al. Inhibition of herpes simplex virus type 1 ribonucleotide reductase by substituted tetrapeptide derivatives
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
JP2003522185A5 (cg-RX-API-DMAC7.html)
WO2008136470A1 (ja) Hcv遺伝子
JP2008517998A5 (cg-RX-API-DMAC7.html)
JP2008508363A5 (cg-RX-API-DMAC7.html)
WO2004064780A3 (en) Peptide-based angiogenesis inhibitors and methods of use thereof